U.S. Markets open in 4 hrs 47 mins

Finch Therapeutics Group, Inc. (FNCH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.5200+0.0450 (+9.47%)
At close: 04:00PM EST
0.5000 -0.02 (-3.85%)
Pre-Market: 04:01AM EST

Finch Therapeutics Group, Inc.

200 Inner Belt Road
Suite 400
Somerville, MA 02143
United States
617 229 6499

Full Time Employees189

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark Burnham Smith Ph.D.CEO & Director698.66kN/A1987
Mr. Marc B. Blaustein C.F.A., CFA, MPPCOO, Principal Financial & Accounting Officer378.21kN/A1963
Mr. Joseph D. Vittiglio Esq., J.D.Chief Bus. & Legal Officer and Corp. Sec.526.08kN/A1972
Mr. Bryan Gillis M.B.A.Chief Technology OfficerN/AN/AN/A
Mr. James S. SiglerExec. VP of CMCN/AN/A1961
Ms. Sonia TimberlakeSr. VP of ResearchN/AN/AN/A
Dr. Howard Franklin M.B.A., M.D.Interim Chief Medical OfficerN/AN/AN/A
Dr. Alka Batycky Ph.D.Chief Devel. OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Corporate Governance

Finch Therapeutics Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.